SCHEMBL352738

SCHEMBL352738

CN(Cc1csc(NC(=O)NCc2cc(Cl)c3c(c2)OCO3)n1)C(=O)[C@H]1CCCO1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.38
LMNA P02545 5/20 0.38
MAPK1 P28482 4/20 0.38
HPGD P15428 2/20 0.38
RAB9A P51151 4/20 0.36
KDM4E B2RXH2 2/20 0.35
CPT1A P50416 4/20 0.35
CPT1B Q92523 4/20 0.35
CPT2 P23786 2/20 0.35
ROCK1 Q13464 1/20 0.35
NPC1 O15118 4/20 0.34
ALDH1A1 P00352 4/20 0.34
ELOVL1 Q9BW60 1/20 0.34
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
POLB P06746 1/20 0.33
CLK1 P49759 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352739 1.00 SMN1; SMN2 (0.38) SMN1; SMN2LMNAMAPK1HPGDRAB9A
SCHEMBL354473 0.85 SMN1; SMN2 (0.42) SMN1; SMN2LMNAMAPK1HPGDRAB9A
SCHEMBL353708 0.80 SMN1; SMN2 (0.42) SMN1; SMN2LMNAMAPK1HPGDRAB9A
SCHEMBL353388 0.80 ROCK2 (0.50) SMN1; SMN2LMNARAB9AKDM4EROCK1
SCHEMBL353453 0.80 ROCK2 (0.50) SMN1; SMN2LMNARAB9AKDM4EROCK1
SCHEMBL354062 0.80 ROCK2 (0.50) SMN1; SMN2LMNARAB9AKDM4EROCK1
SCHEMBL353243 0.79 SMN1; SMN2 (0.39) SMN1; SMN2LMNAMAPK1HPGDRAB9A
SCHEMBL353295 0.78 ROCK2 (0.49) SMN1; SMN2LMNARAB9AROCK1NPC1
SCHEMBL353754 0.77 SMN1; SMN2 (0.42) SMN1; SMN2LMNAMAPK1HPGDRAB9A
SCHEMBL353755 0.77 SMN1; SMN2 (0.42) SMN1; SMN2LMNAMAPK1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO claimed
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA SMN1; SMN2 2356/4885LMNA 4293/4885MAPK1 3630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.